Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
The occurrence and development of cancer are closely related to the immune escape of tumor cells and immune tolerance. Unlike previous surgical, chemotherapy, radiotherapy and targeted therapy, tumor immunotherapy is a therapeutic strategy that uses various means to stimulate and enhance the immune...
Guardado en:
Autores principales: | Zhitao Li, Guoqiang Sun, Guangshun Sun, Ye Cheng, Liangliang Wu, Qian Wang, Chengyu Lv, Yichan Zhou, Yongxiang Xia, Weiwei Tang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/dbccacbd762c4d9bb560d433c84be82a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
por: Peiyi Xie, et al.
Publicado: (2021) -
Dl-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling
por: Jiang Q, et al.
Publicado: (2021) -
Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy
por: Myeong Joon Kim, et al.
Publicado: (2021) -
Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
por: Miao Wang, et al.
Publicado: (2021) -
Regulatory Mechanism of PD-L1 Expression in Primary Liver Cancer
por: LI Shenghao, et al.
Publicado: (2021)